Latest filing published 09 Jan 2024 for EyePoint Pharmaceuticals, Inc..
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Michael Craig Pine: trading record in brief
Michael Craig Pine, listed as senior executive, appears in our data through filings on EyePoint, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 14 March 2022 to 6 January 2024, the count stands at 8 filings.
Both buying and selling appear: 1 purchase worth €11k, against 3 sales worth €1.8M. Netting one side against the other leaves €1.8M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 share grant and 3 option exercises.
Most recently, on 9 January 2024, the filings show a share grant worth €111k in EyePoint, Inc. The clock since the last published purchase (15 March 2022) now reads 1,701 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Michael Craig Pine
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 15,285 shares0Common StockSEC:0001562180-24-000400:0
- 45,000 shares@ US$12.6249.5% of flowCommon StockSEC:0001562180-23-008273:0
- 45,000 shares@ US$12.6249.5% of flowCommon StockSEC:0001562180-23-008172:0
- 1,000 shares@ US$12.212.1% of flowCommon StockSEC:0001562180-22-002643:0Canonical exit: 12 Jun 2022 (T+90)
4 of 4 declarations